Relapse after allogeneic stem cell transplantation

Expert Review of Hematology

Volumn 3, Issue 4, 2010, Pages 429-441

  Barrett, A John ^a   Battiwalla, Minoo ^a  

^a MSC 1202 ^*  (United States)

Author keywords

bone marrow transplant; donor lymphocyte infusion; graft versus leukemia; relapse; second transplant

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; ANTHRACYCLINE; AZACITIDINE; BORTEZOMIB; CD20 ANTIBODY; CLOFARABINE; CYCLOSPORIN A; CYTOSINE; DASATINIB; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; IMATINIB; INTERLEUKIN 2; LENALIDOMIDE; MONOCLONAL ANTIBODY; NILOTINIB; PEPTIDE VACCINE; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THALIDOMIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW APLASIA; CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; GRANULOCYTIC SARCOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEUKEMIA RELAPSE; MICROENVIRONMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REMISSION; REVIEW; TUMOR SUPPRESSOR GENE;

HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77955595601     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.32     Document Type: Review

References (105)

1. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: part I-CIBMTR summary slides. CIBMTR Newsletter (serial online) 15(1), 7-11 (2009).
2. Barrett AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br. J. Haematol. 142(6), 877-888 (2008).
3. Murata M, Ishikawa Y, Ohashi H et al. Donor cell leukemia after allogeneic peripheral blood stem cell transplantation: a case report and literature review. Int. J. Hematol. 88(1), 111-115 (2008).
4. Ruiz-Arguelles GJ, Ruiz-Arguelles A, Garces-Eisele J. Donor cell leukemia: a critical review. Leuk. Lymphoma 48(1), 25-38 (2007).
5. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3(11), 999-1005 (2002).
6. Dermime S, Mavroudis D, Jiang YZ, Hensel N, Molldrem J, Barrett AJ. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant. 19(10), 989-999 (1997).
7. Vago L, Perna SK, Zanussi M et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N. Engl. J. Med. 361(5), 478-488 (2009).
8. Villalobos IB, Takahashi Y, Akatsuka Y et al. Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. Blood 115(15), 3158-3161 (2010).
9. Boatsman EE, Fu CH, Song SX, Moore TB. Graft-versus-leukemia effect on infant lymphoblastic leukemia relapsed after sibling hematopoietic stem cell transplantation. J. Pediatr. Hematol. Oncol. 32(2), e57-e60 (2009).
10. Elmaagacli AH, Beelen DW, Schaefer UW. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 20(12), 1045-1055 (1997).
11. Savani BN, Mielke S, Rezvani K et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 13(10), 1216-1223 (2007).
12. Savani BN, Mielke S, Adams S et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 21(10), 2145-2152 (2007).
13. Shlomchik WD, Couzens MS, Tang CB et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285(5426), 412-415 (1999).
14. Collin MP, Bogunovic M, Merad M. DC homeostasis in hematopoietic stem cell transplantation. Cytotherapy 9(6), 521-531 (2007). (Pubitemid 47457003)
15. Rezvani K, Mielke S, Ahmadzadeh M et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108(4), 1291-1297 (2006).
16. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077), 682-687 (2006).
17. Ocheni S, Iwanski GB, Schafhausen P et al. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk. Lymphoma 50(4), 551-558 (2009).
18. Sackstein R. A revision of Billinghams tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol. Blood Marrow Transplant. 12(1 Suppl. 1), 2-8 (2006).
19. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464), 645-648 (1994).
20. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 41(5), 483-493 (2008).
21. Shaw BE, Mufti GJ, Mackinnon S et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant. 42(12), 783-789 (2008).
22. Platzbecker U, Thiede C, Freiberg-Richter J et al. Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF. Ann. Hematol. 80(3), 144-149 (2001).
23. Al-Qurashi F, Ayas M, Al Sharif F et al. Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution. Hematology 9(2), 123-129 (2004).
24. Eapen M, Giralt SA, Horowitz MM et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 34(8), 721-727 (2004).
25. Michallet M, Tanguy ML, Socie G et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br. J. Haematol. 108(2), 400-407 (2000).
26. Hosing C, Saliba RM, Shahjahan M et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant. 36(2), 157-162 (2005).
27. Mrsic M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant. 9(4), 269-275 (1992).
28. Michallet AS, Nicolini F, Furst S et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant. 35(6), 601-608 (2005).
29. Mielcarek M, Storer BE, Flowers ME, Storb R, Sandmaier BM, Martin PJ. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 13(10), 1160-1168 (2007).
30. Bader P, Kreyenberg H, Hoelle W et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J. Clin. Oncol. 22(9), 1696-1705 (2004).
31. Diez-Campelo M, Perez-Simon JA, Perez J et al. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am. J. Hematol. 84(3), 149-152 (2009).
32. Bacher U, Zander AR, Haferlach T, Schnittger S, Fehse B, Kroger N. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant. 42(3), 145-157 (2008).
33. Sramkova L, Muzikova K, Fronkova E et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr. Blood Cancer 48(1), 93-100 (2007).
34. Candoni A, Tiribelli M, Toffoletti E et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur. J. Haematol. 82(1), 61-68 (2009).
35. Pollyea DA, Artz AS, Stock W et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 40(11), 1027-1032 (2007).
36. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol. Blood Marrow Transplant. 13(1), 116-123 (2007).
37. Barrett AJ, Joshi R, Tew C. How should acute lymphoblastic leukaemia relapsing after bone-marrow transplantation be treated? Lancet 1(8439), 1188-1191 (1985).
38. Abrahamsson J, Clausen N, Gustafsson G et al. Improved outcome after relapse in children with acute myeloid leukaemia. Br. J. Haematol. 136(2), 229-236 (2007).
39. Hijiya N, Gaynon P, Barry E et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 23(12), 2259-2264 (2009).
40. Safaian NN, Czibere A, Bruns I et al. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk. Res. 33(2), 348-350 (2009).
41. Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia- positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk. Res. 33(1), 174-177 (2009).
42. Imahashi N, Tokunaga M, Nishiwaki S, Yanagisawa M, Ozawa Y, Miyamura K. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation. Rinsho Ketsueki 50(11), 1612-1615 (2009).
43. Jabbour E, Giralt S, Kantarjian H et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer, 115(9), 1899-1905 (2009).
44. Ravandi F, Kantarjian H, Cohen A et al. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a Phase I study. Bone Marrow Transplant. 27(12), 1221-1225 (2001).
45. Ford CD, Asch J, Konopa K, Petersen FB. CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT. Bone Marrow Transplant. 45(2), 403-404 (2010).
46. Levine JE, Barrett AJ, Zhang MJ et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant. 42(3), 201-205 (2008).
47. Schmid C, Labopin M, Nagler A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J. Clin. Oncol. 25(31), 4938-4945 (2007).
48. Lubbert M, Bertz H, Wasch R et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed afterallografting. Bone Marrow Transplant. 45(4), 627-632 (2009).
49. Levine JE, Braun T, Penza SL et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J. Clin. Oncol. 20(2), 405-412 (2002).
50. Savani BN, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant. 44(12), 769-777 (2009).
51. Thakar MS, Forman SJ. ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse? Hematology Am. Soc. Hematol. Educ. Program 414-418 (2009).
52. Kurosawa S, Fukuda T, Tajima K et al. Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation. Am. J. Hematol. 84(12), 815-820 (2009).
53. Hartwig M, Ocheni S, Asenova S et al. Second allogeneic stem cell transplantation in myeloid malignancies. Acta Haematol. 122(4), 185-192 (2009).
54. Tringali S, Vasta S, Scime R, Catania P, Cavallaro AM, Majolino I. Testicular relapse of AML during chronic graft-versus-host disease induced by donor leukocyte infusion. Haematologica 81(4), 339-342 (1996).
55. Szomor A, Passweg JR, Tichelli A, Hoffmann T, Speck B, Gratwohl A. Myeloid leukemia and myelodysplastic syndrome relapsing as granulocytic sarcoma (chloroma) after allogeneic bone marrow transplantation. Ann. Hematol. 75(5-6), 239-241 (1997). (Pubitemid 27526241)
56. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76(12), 2462-2465 (1990).
57. Chalandon Y, Passweg JR, Schmid C et al. Outcome of patients developing GVHD after given to treat CML relapse: a study by the chronic leukemia working party of the EBMT. Bone Marrow Transplant. 45(3), 558-564 (2010).
58. Raiola AM, Van Lint MT, Valbonesi M et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant. 31(8), 687-693 (2003).
59. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86(4), 1261-1268 (1995).
60. Keil F, Haas OA, Fritsch G et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 89(9), 3113-3117 (1997).
61. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86(5), 2041-2050 (1995).
62. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15(2), 433-444 (1997).
63. Kantarjian HM, OBrien S, Cortes JE et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100(5), 1590-1595 (2002).
64. Barrett AJ, Locatelli F, Treleaven JG, Gratwohl A, Szydlo R, Zwaan FE. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br. J. Haematol. 79(4), 567-574 (1991).
65. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109(8), 3588-3594 (2007).
66. Hari P, Carreras J, Zhang MJ et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol. Blood Marrow Transplant. 14(2), 236-245 (2008).
67. Ringden O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft-versus-cancer effect. Br. J. Haematol. 147(5), 614-633 (2009).
68. Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol. Blood Marrow Transplant. 10(9), 579-590 (2004).
69. Khouri IF, McLaughlin P, Saliba RM et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12), 5530-5536 (2008).
70. Escalon MP, Champlin RE, Saliba RM et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkins lymphoma whose disease has failed a prior autologous transplantation. J. Clin. Oncol. 22(12), 2419-2423 (2004).
71. Khouri IF, Lee MS, Saliba RM et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J. Clin. Oncol. 21(23), 4407-4412 (2003).
72. Mehta J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplant. 22(9), 835-843 (1998).
73. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90(10), 4206-4211 (1997).
74. Salama M, Nevill T, Marcellus D et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant. 26(11), 1179-1184 (2000).
75. Bloor AJ, Thomson K, Chowdhry N et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol. Blood Marrow Transplant. 14(1), 50-58 (2008).
76. Russell NH, Byrne JL, Faulkner RD, Gilyead M, Das-Gupta EP, Haynes AP. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 36(5), 437-441 (2005).
77. Kroger N, Alchalby H, Klyuchnikov E et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood, 113(8), 1866-1868 (2009).
78. Cavattoni I, Zabelina T, Ayuk F et al. Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation. Leuk. Lymphoma 51(1), 146-148).
79. Vesole DH, Zhang L, Flomenberg N, Greipp PR, Lazarus HM, Huff CA. A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biol. Blood Marrow Transplant. 15(1), 83-91 (2009).
80. Blair A, Goulden NJ, Libri NA, Oakhill A, Pamphilon DH. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev. 19(6), 289-300 (2005).
81. Armand P, Gannamaneni S, Kim HT et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J. Clin. Oncol. 26(35), 5767-5774 (2008).
82. Cutler C, Kim HT, Hochberg E et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol. Blood Marrow Transplant. 10(5), 328-336 (2004).
83. Lundqvist A, Abrams SI, Schrump DS et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 66(14), 7317-7325 (2006).
84. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J. Clin. Oncol. 26(9), 1544-1552 (2008).
85. Soiffer RJ, Weller E, Alyea EP et al. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J. Clin. Oncol. 19(4), 1152-1159 (2001).
86. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276(5319), 1719-1724 (1997).
87. Onodera M. Gene and cell therapy for relapsed leukemia after allo-stem cell transplantation. Front Biosci. 13, 3408-3414 (2008).
88. Falkenburg JH, Wafelman AR, Joosten P et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 94(4), 1201-1208 (1999).
89. Warren EH, Fujii N, Akatsuka Y et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplant with T cells specific for minor histocompatibility antigens. Blood 115(19), 3869-3878 (2010).
90. Bleakley M, Otterud BE, Richardt JL et al. Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood DOI: blood-2009-2012-260539 (2010) (Epub ahead of print).
91. Berry LJ, Moeller M, Darcy PK. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens 74(4), 277-289 (2009).
92. Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr. Opin. Immunol. 21(5), 525-530 (2009).
93. Cooley S, Trachtenberg E, Bergemann TL et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113(3), 726-732 (2009).
94. Stringaris K, Adams S, Uribe M et al. Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukaemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukaemia but not other haematological malignancies. Biol. Blood Marrow Transplant. DOI: 10.1016/j. bbmt.2010.03.004 (2010) (Epub ahead of print).
95. Yong AS, Keyvanfar K, Hensel N et al. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 113(4), 875-882 (2009).
96. Berger C, Berger M, Hackman RC et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114(12), 2417-2426 (2009).
97. Lu Y, Waller EK. Dichotomous role of interferon-g in allogeneic bone marrow transplant. Biol. Blood Marrow Transplant. 15(11), 1347-1353 (2009).
98. Kujawski LA, Talpaz M. The role of interferon-a in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 18(5-6), 459-471 (2007). (Pubitemid 47302836)
99. Waller EK. The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist 12(Suppl. 2), 22-26 (2007).
100. Morris JC, Waldmann TA. Antibody-based therapy of leukaemia. Expert Rev. Mol. Med. 11, e29 (2009).
101. Barrett AJ, Rezvani K. Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clin. Exp. Immunol. 148(2), 189-198 (2007).
102. Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract. Res. Clin. Haematol. 21(3), 437-453 (2008).
103. Barrett J, Rezvani K. Immunotherapy: can we include vaccines with stem-cell transplantation? Nat. Rev. Clin. Oncol. 6(9), 503-505 (2009).
104. Miller JS, Warren EH, Vandenbrink MR et al. NCI 1st International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biology underlying recurrence of malignant disease following allogeneic hsct: graft-versus-tumor/leukemia reaction. Biol. Blood Marrow Transplant. 16(5), 565-586 (2010).
105. van den Brink MR, Porter DL, Giralt S et al. Relapse after allogeneic hematopoietic cell therapy. Biol. Blood Marrow Transplant. 16(1 Suppl.), S138-S145 (2010).